olodaterol (BI 1744) low

DRUG2 trials

Sponsors

Boehringer Ingelheim

Conditions

AsthmaPulmonary Disease, Chronic Obstructive

Phase 2

A Study of the Safety and Efficacy of 4 Doses of BI 1744 CL Delivered Via the Respimat in Patients With Asthma.

CompletedNCT01013753

Boehringer IngelheimAsthma

Start: 2010-02-28End: 2011-01-31Updated: 2014-06-27

Determining Optimal Free Dose Combination of Tiotropium Bromide and BI 1744 CL in Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT01040403

Boehringer IngelheimPulmonary Disease, Chronic Obstructive

Start: 2010-01-31Updated: 2015-07-15

Related Papers

Optimizing the Development Strategy of Combination Therapy in Respiratory Medicine: From Isolated Airways to Patients.

2019-10-2519 citations

Dose Determination for a Fixed-Dose Drug Combination: A Phase II Randomized Controlled Trial for Tiotropium/Olodaterol Versus Tiotropium in Patients with COPD.

2019-03-067 citations

Randomized, Double-Blind, Dose-Finding Study for Tiotropium when Added to Olodaterol, Administered via the Respimat® Inhaler in Patients with Chronic Obstructive Pulmonary Disease

Advances in Therapy2015-09-0116 citations

Dose-finding evaluation of once-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with asthma: results of a parallel-group study and a crossover study

Respiratory Research2015-08-1713 citations

Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat® in patients with moderate to severe persistent asthma.

2015-07-167 citations